Steven Sherman

Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

Allison Perrin, Steven Sherman, Sumanta K. Pal et al. · Journal of Medical Economics · 2014 · 42 citations · Full text

Medicine, Oncology, Pharmacoeconomics +15

Resource Utilization and Cost of Heart Failure associated with Reduced Ejection Fraction in Swedish Patients

Jan Stålhammar, Lee Stern, Ragnar Linder et al. · Journal of Medical Economics · 2012 · 29 citations

Medicine, Cardiology, Internal Medicine +14

Bivalirudin Therapy Is Associated With Improved Clinical and Economic Outcomes in ST-Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: Results From an Observational Database

Duane S. Pinto, Augustina Ogbonnaya, Steven Sherman et al. · Circulation Cardiovascular Quality and Outcomes · 2012 · 28 citations · Full text

Medicine, Cardiology, Pharmacoeconomics +17

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

Giuseppe Di Lorenzo, Roman Casciano, Elisabetta Malangone et al. · Expert Opinion on Pharmacotherapy · 2011 · 27 citations

Medicine, Oncology, Pharmacotherapy +13

An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed

Steven Sherman, Billy Amzal, Emiliano Calvo et al. · Clinical Therapeutics · 2015 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17